risperidone has been researched along with Acute Disease in 134 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 9.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics." | 9.20 | Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. ( Bergmans, P; Bez, Y; Carpiniello, B; Cherubin, P; Hargarter, L; Keim, S; Parellada, E; Rancans, E; Schreiner, A; Vidailhet, P, 2015) |
| "We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses." | 9.17 | The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. ( Hatta, K; Hirata, T; Ito, S; Kasuya, M; Katayama, S; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Nakase, R; Ohnuma, T; Sawa, Y; Shirai, Y; Sudo, Y; Takebayashi, H; Usui, C, 2013) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | 9.16 | Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 9.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." | 9.13 | Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. ( Azzoni, A; Raja, M, 2008) |
| " Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested." | 9.12 | Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007) |
| "This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization." | 9.12 | A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. ( Bossie, CA; Burtea, V; Davidson, M; Gharabawi, GM; Greenspan, AJ; Kosik-Gonzalez, C; Mahmoud, R; Potkin, SG; Rupnow, MF; Trivedi, JK; Zhu, Y, 2006) |
| "This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria)." | 9.12 | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. ( Cohen, M; Panagides, J; Potkin, SG, 2007) |
| " This study evaluated treatment practices over 7 years of initial treatment with oral risperidone in acutely exacerbated patients with schizophrenia and in a subgroup of highly agitated, tense, and aggressive patients." | 9.11 | Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2005) |
| "Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia." | 9.11 | Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. ( Chang, YC; Chiu, CC; Lane, HY; Liu, YC; Tsai, GE, 2005) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 9.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone." | 9.10 | Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. ( Chang, WH; Chang, YC; Cheng, YC; Lane, HY; Lin, XR; Liu, GC, 2003) |
| "We have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons." | 9.10 | Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. ( Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R, 2003) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "The optimal risperidone dosing strategy for acute schizophrenia requires elucidation." | 9.09 | Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. ( Chang, WH; Chiu, WC; Chou, JC; Lane, HY; Su, MH; Wu, ST, 2000) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 9.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 8.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 8.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression." | 7.83 | Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1. ( Li, C; Li, J, 2016) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 7.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| "Twenty-five antipsychotic drug-naive, acutely ill patients with first-episode schizophrenia performed an oculomotor delayed response task at baseline before any drug treatment and again after 6 weeks of risperidone treatment." | 7.73 | Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. ( Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA, 2006) |
| " High-dose treatment with risperidone may be more beneficial in males for the treatment of acute schizophrenia." | 7.73 | Gender-specific effects in the treatment of acute schizophrenia with risperidone. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2006) |
| "To report a case of delirium with hallucinations presumably caused by the combination of diphenhydramine and linezolid." | 7.72 | Acute delirium associated with combined diphenhydramine and linezolid use. ( Serio, RN, 2004) |
| "We report a case of rhabdomyolysis and acute compartment syndrome of the lower extremity in a schizophrenic patient taking risperidone following the addition of simvastatin to treat hyperlipidemia." | 7.72 | Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. ( Lightfoot, JD; Mahmud, W; Shekhar, A; Webber, MA, 2004) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | 5.51 | Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| " A population pharmacokinetic modeling approach was used to estimate the interindividual variability of the pharmacokinetic parameters in 50 hospitalized patients with acute episode of schizophrenia." | 5.36 | A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Kores-Plesnicar, B; Locatelli, I; Mrhar, A, 2010) |
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 5.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "Treatment with risperidone was offered to acutely psychotic schizophrenic patients with the requirement of a minimum score of > or =4 on 2 items of the PANSS positive symptoms subscale." | 5.32 | Risperidone in the treatment of acute schizophrenia. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2004) |
| "In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics." | 5.20 | Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. ( Bergmans, P; Bez, Y; Carpiniello, B; Cherubin, P; Hargarter, L; Keim, S; Parellada, E; Rancans, E; Schreiner, A; Vidailhet, P, 2015) |
| "We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses." | 5.17 | The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. ( Hatta, K; Hirata, T; Ito, S; Kasuya, M; Katayama, S; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Nakase, R; Ohnuma, T; Sawa, Y; Shirai, Y; Sudo, Y; Takebayashi, H; Usui, C, 2013) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | 5.16 | Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| " Patients, 13-17 years, with an acute episode of schizophrenia, randomised 1:1 to risperidone 1." | 5.14 | Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. ( Augustyns, I; Eerdekens, M; Haas, M; Kushner, S; Kusumakar, V; Pandina, G; Quiroz, J; Singer, J, 2009) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 5.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." | 5.13 | Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. ( Azzoni, A; Raja, M, 2008) |
| "This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization." | 5.12 | A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. ( Bossie, CA; Burtea, V; Davidson, M; Gharabawi, GM; Greenspan, AJ; Kosik-Gonzalez, C; Mahmoud, R; Potkin, SG; Rupnow, MF; Trivedi, JK; Zhu, Y, 2006) |
| " Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested." | 5.12 | Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007) |
| "This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria)." | 5.12 | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. ( Cohen, M; Panagides, J; Potkin, SG, 2007) |
| "Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia." | 5.11 | Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. ( Chang, YC; Chiu, CC; Lane, HY; Liu, YC; Tsai, GE, 2005) |
| " This study evaluated treatment practices over 7 years of initial treatment with oral risperidone in acutely exacerbated patients with schizophrenia and in a subgroup of highly agitated, tense, and aggressive patients." | 5.11 | Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2005) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 5.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "In a double-blind, fixed-dose study, 49 acutely psychotic, neuroleptic-naive patients who were admitted for the first time and who met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder were randomly assigned to 2 or 4 mg/day of risperidone." | 5.10 | Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. ( Berger, G; Gekle, W; Hofer, H; Latour, G; Marder, SR; Merlo, MC; Panhuber, I; Ventura, J, 2002) |
| "We have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons." | 5.10 | Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. ( Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R, 2003) |
| "The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone." | 5.10 | Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. ( Chang, WH; Chang, YC; Cheng, YC; Lane, HY; Lin, XR; Liu, GC, 2003) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol." | 5.10 | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002) |
| "The optimal risperidone dosing strategy for acute schizophrenia requires elucidation." | 5.09 | Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. ( Chang, WH; Chiu, WC; Chou, JC; Lane, HY; Su, MH; Wu, ST, 2000) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 5.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "A double-blind, randomized, multi-center, parallel-group study was conducted in Finland to compare the efficacy and safety of risperidone with zuclopenthixol in patients with acute exacerbations of schizophrenia or schizophreniform disorder." | 5.08 | Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. ( Huttunen, MO; Larmo, I; Nyholm, R; Piepponen, T; Raitasuo, V; Rantanen, H, 1995) |
| "A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms." | 5.05 | Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. ( Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020) |
| "Treatment of acute mania with second-generation antipsychotics has been claimed to involve a lower risk of switch to depression than haloperidol." | 4.89 | Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 4.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "This article reviews the evidence for the efficacy and effectiveness of risperidone in persons with schizophrenia." | 4.79 | Risperidone: efficacy and safety. ( Kane, JM; Umbricht, D, 1995) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 4.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "Clozapine is a second-generation antipsychotic typically reserved for refractory psychotic disorders due to its high-risk side effect profile to include agranulocytosis, with its attendant need for regular blood draws." | 3.91 | An Unexpected Circumstance: Acute Dystonic Reaction in the Setting of Clozapine Administration. ( Ahmed, I; Kaplan, AM; Pitts, WB, 2019) |
| "The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression." | 3.83 | Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1. ( Li, C; Li, J, 2016) |
| "The study involved 64 first-episode schizophrenia patients treated with the second-generation oral antipsychotic medication, risperidone, for 12 months." | 3.80 | The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia. ( Agee, ER; Casaus, LR; Gretchen-Doorly, D; Hellemann, GS; Luo, JS; Nuechterlein, KH; Subotnik, KL; Ventura, J; Villa, KF, 2014) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 3.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| " Consecutively hospitalized, acutely psychotic patients with DSM-IV schizophrenia (n=121) were included in the study if they received treatment with typical antipsychotic medication (TYP, n=72) or TYP plus risperidone (TYP-R, n=49) for at least 2 wk." | 3.74 | Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. ( Ben-Asher, E; Deshpande, SN; Greenbaum, L; Horowitz, A; Kanyas, K; Karni, O; Lancet, D; Lerer, B; Merbl, Y; Olender, T; Strous, RD; Viglin, D, 2007) |
| "To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5-20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10-20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology." | 3.74 | Evaluating dose response from flexible dose clinical trials. ( Adams, DH; Baron, D; Faries, D; Houston, JP; Lipkovich, I; Mallinckrodt, C, 2008) |
| " His hallucinations and delusions remitted after treatment with risperidone, paralleling motor improvement." | 3.74 | Psychosis following acute Sydenham's chorea. ( Cardoso, F; Maia, DP; Teixeira, AL, 2007) |
| "Twenty-five antipsychotic drug-naive, acutely ill patients with first-episode schizophrenia performed an oculomotor delayed response task at baseline before any drug treatment and again after 6 weeks of risperidone treatment." | 3.73 | Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. ( Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA, 2006) |
| " High-dose treatment with risperidone may be more beneficial in males for the treatment of acute schizophrenia." | 3.73 | Gender-specific effects in the treatment of acute schizophrenia with risperidone. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2006) |
| "To report a case of delirium with hallucinations presumably caused by the combination of diphenhydramine and linezolid." | 3.72 | Acute delirium associated with combined diphenhydramine and linezolid use. ( Serio, RN, 2004) |
| "We report a case of rhabdomyolysis and acute compartment syndrome of the lower extremity in a schizophrenic patient taking risperidone following the addition of simvastatin to treat hyperlipidemia." | 3.72 | Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. ( Lightfoot, JD; Mahmud, W; Shekhar, A; Webber, MA, 2004) |
| "Topiramate is a novel anticonvulsant agent with a broad spectrum mechanism of action, and recent clinical reports indicate that it may have mood stabilizing properties in bipolar disorder." | 3.71 | Topiramate as a mood stabilizer. ( Kasper, S; Letmaier, M; Schreinzer, D; Wolf, R, 2001) |
| "Risperidone was superior to Quetiapine in decreasing the PANSS general psychopathology sub-scores and total score (p<0." | 2.80 | Comparison of Quetiapine and Risperidone in Treatment of Acute Psychosis: A Double-Blind, Randomized-Controlled Study. ( Ahmadi, M; Mojtahedi, D; Monajemi, MB; Moosavi, SM; Yazdani, J, 2015) |
| "This was a 6-week, multicenter, randomized, open-label, parallel-group, flexible dosing study." | 2.78 | An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. ( Chan, HY; Chen, KP; Chen, YY; Cheng, JS; Lin, AS; Tsai, CJ, 2013) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| "56 male subjects with paranoid schizophrenia were included in the study." | 2.77 | Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. ( Beniashvili, AG; Lepilkina, TA; Morozova, MA; Rupchev, GE, 2012) |
| "A population model was developed with the aim to simultaneously describe risperidone and 9-hydroxyrisperidone pharmacokinetics; to obtain estimates for pharmacokinetic parameters and associated inter- and intra-individual variability of risperidone and 9-hydroxyrisperidone; and to evaluate the influence of patient demographic characteristics and other factors on risperidone, 9-hydroxyrisperidone, and active moiety pharmacokinetics." | 2.73 | Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. ( Ludwig, EA; Piotrovsky, V; Vermeulen, A, 2007) |
| "Lorazepam alone was as effective as lorazepam plus haloperidol or lorazepam plus risperidone in this small trial." | 2.72 | Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. ( Currier, GW; McMullan, JT; Veser, BD; Veser, FH; Zealberg, J, 2006) |
| "Olanzapine-treated patients had significantly more weight gain compared with the haloperidol and risperidone groups (p < ." | 2.72 | A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. ( Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M, 2006) |
| "Risperidone was received by 146 patients and placebo by144." | 2.71 | Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. ( Eerdekens, M; Grossman, F; Khanna, S; Kramer, M; Lyons, B; Vieta, E, 2005) |
| " At the end of the observation, the mean dosage was 5." | 2.71 | [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis]. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2003) |
| " The patients were treated with conventional antipsychotics for seven days after admission and were then randomised to the treatment arms with risperidone (4 mg/day) or with olanzapine (10 mg/day) at a fixed dosage in the first week and thereafter in flexible dosages for the remaining seven weeks." | 2.71 | Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. ( Kores Plesnicar, B; Krajnc, I; Tomori, M; Zalar, B, 2003) |
| " Treatment was naturalistic, and dosing was based on the discretion of the treating physician." | 2.71 | Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. ( Cook, A; Kraus, JE; Lieberman, JA; Reviere, R; Sheitman, BB, 2005) |
| "Risperidone monotherapy was significantly more efficacious than placebo in the treatment of acute mania and demonstrated a rapid onset of action." | 2.71 | Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. ( Canuso, C; Eerdekens, M; Grossman, F; Hirschfeld, RM; Karcher, K; Keck, PE; Kramer, M, 2004) |
| "Risperidone was generally well tolerated." | 2.71 | Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. ( Bahk, WM; Choi, SK; Kim, KS; Kim, YH; Lee, C; Lee, YH; Pae, CU; Song, HK; Yoon, JS, 2004) |
| " Mean score improvements at 30, 60, and 120 minutes after dosing were significant at each timepoint in both groups (p <." | 2.71 | Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. ( Bossie, CA; Chou, JC; Currier, GW; Feifel, D; Gharabawi, GM; Mahmoud, RA; Turkoz, I, 2004) |
| " The aim of this study was to compare the effectiveness and tolerability of topiramate and divalproex in combination with risperidone for treating acute mania patients in a naturalistic treatment setting." | 2.71 | Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. ( Bahk, WM; Choi, SK; Chung, SK; Jon, DI; Lee, JS; Pae, CU; Paik, IH; Shin, YC; Woo, JM; Yoon, BH, 2005) |
| " It also appears that rapid dosage increases for antimanic treatment can cause potentially severe side effects." | 2.69 | Tiagabine appears not to be efficacious in the treatment of acute mania. ( Amann, B; Erfurth, A; Grunze, H; Marcuse, A; Normann, C; Walden, J, 1999) |
| "The effects of neuroleptics on bipolar depression need further study." | 2.39 | Antipsychotics in bipolar disorder. ( Gelenberg, AJ; Hopkins, HS, 1996) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | 1.51 | Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| "Risperidone pretreatment significantly attenuated increases in the levels of DA, 5-HT, glutamate, and NOx." | 1.36 | Effect of risperidone on acute methamphetamine-induced hyperthermia in rats. ( Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2010) |
| " A population pharmacokinetic modeling approach was used to estimate the interindividual variability of the pharmacokinetic parameters in 50 hospitalized patients with acute episode of schizophrenia." | 1.36 | A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Kores-Plesnicar, B; Locatelli, I; Mrhar, A, 2010) |
| "Treatment with risperidone solution orally or parenteral haloperidol until the day after admission, followed by olanzapine, successfully improved the clinical condition of the patients." | 1.35 | Three cases of schizophrenia for which olanzapine was effective after early acute phase. ( Inada, T; Oda, T; Yamamoto, N, 2008) |
| "Risperidone is an atypical neuroleptic drug widely used due to the lower incidence and severity of hepatic adverse effects in comparison to phenothiazines." | 1.33 | Acute cholestatic hepatitis probably associated with risperidone. ( Bosacoma Ros, N; Climent Grana, E; Hernández Prats, C; Llinares Tello, F; Navarro Polo, JN; Ordovás Baines, JP; Pérez Martínez, E, 2005) |
| "Acute confusional state (delirium) appears as one of the common neuropsychiatric manifestations of systemic lupus erythematosus (SLE)." | 1.32 | Risperidone in the treatment of acute confusional state (delirium) due to neuropsychiatric lupus erythematosus: case report. ( Furuya, T; Harigai, M; Horikawa, N; Nishimura, K; Omori, M; Tanaka, E, 2003) |
| "Treatment with risperidone was offered to acutely psychotic schizophrenic patients with the requirement of a minimum score of > or =4 on 2 items of the PANSS positive symptoms subscale." | 1.32 | Risperidone in the treatment of acute schizophrenia. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2004) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | 1.31 | Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000) |
| "Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications." | 1.31 | Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. ( Currier, GW; Simpson, GM, 2001) |
| "Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded." | 1.31 | Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002) |
| " A full pharmacokinetic time profile of lithium was obtained." | 1.31 | Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. ( Beijnen, JH; Kerbusch, T; Mathôt, RA; Meesters, EW; Otten, HM; Schellens, JH; van Kan, HJ, 2002) |
| "Risperidone is a new benzisoxazole derivative displaying a very potent serotonin antagonism and a potent dopamine antagonism in pharmacological studies." | 1.28 | Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. ( Kissling, W; Möller, HJ; Pelzer, E; Riehl, T; Wernicke, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (16.42) | 18.2507 |
| 2000's | 84 (62.69) | 29.6817 |
| 2010's | 24 (17.91) | 24.3611 |
| 2020's | 4 (2.99) | 2.80 |
| Authors | Studies |
|---|---|
| Naguy, A | 1 |
| Roshdy, R | 1 |
| Alamiri, B | 1 |
| Schaefer, M | 1 |
| Sarkar, S | 1 |
| Theophil, I | 1 |
| Leopold, K | 1 |
| Heinz, A | 2 |
| Gallinat, J | 1 |
| Leucht, S | 1 |
| Crippa, A | 1 |
| Siafis, S | 1 |
| Patel, MX | 1 |
| Orsini, N | 1 |
| Davis, JM | 2 |
| Parker, C | 1 |
| Slan, A | 1 |
| Shalev, D | 1 |
| Critchfield, A | 1 |
| Kudlek Mikulic, S | 1 |
| Mihaljevic-Peles, A | 1 |
| Sagud, M | 1 |
| Bajs Janovic, M | 1 |
| Ganoci, L | 1 |
| Grubisin, J | 1 |
| Kuzman Rojnic, M | 1 |
| Vuksan Cusa, B | 1 |
| Bradaš, Z | 1 |
| Božina, N | 1 |
| Kaplan, AM | 1 |
| Pitts, WB | 1 |
| Ahmed, I | 1 |
| Earley, W | 1 |
| Guo, H | 1 |
| Daniel, D | 1 |
| Nasrallah, H | 1 |
| Durgam, S | 1 |
| Zhong, Y | 1 |
| Patel, M | 1 |
| Barabássy, Á | 1 |
| Szatmári, B | 1 |
| Németh, G | 1 |
| Yoshimura, B | 1 |
| Sato, K | 1 |
| Sakamoto, S | 1 |
| Tsukahara, M | 1 |
| Yoshimura, Y | 1 |
| So, R | 1 |
| Hatta, K | 2 |
| Takebayashi, H | 2 |
| Sudo, Y | 2 |
| Katayama, S | 2 |
| Kasuya, M | 1 |
| Shirai, Y | 2 |
| Morikawa, F | 2 |
| Nakase, R | 2 |
| Nakamura, M | 2 |
| Ito, S | 2 |
| Kuga, H | 1 |
| Ohnuma, T | 1 |
| Usui, C | 2 |
| Nakamura, H | 2 |
| Hirata, T | 2 |
| Sawa, Y | 2 |
| Chan, HY | 1 |
| Lin, AS | 1 |
| Chen, KP | 1 |
| Cheng, JS | 1 |
| Chen, YY | 1 |
| Tsai, CJ | 1 |
| Murphy, RA | 1 |
| Hallahan, B | 1 |
| Otachi, T | 1 |
| Fujita, K | 1 |
| Tomiyama, H | 1 |
| Abe, T | 1 |
| Yamashita, T | 1 |
| Ito, H | 1 |
| Subotnik, KL | 1 |
| Ventura, J | 2 |
| Gretchen-Doorly, D | 1 |
| Hellemann, GS | 1 |
| Agee, ER | 1 |
| Casaus, LR | 1 |
| Luo, JS | 1 |
| Villa, KF | 1 |
| Nuechterlein, KH | 1 |
| Hargarter, L | 1 |
| Cherubin, P | 1 |
| Bergmans, P | 1 |
| Keim, S | 1 |
| Rancans, E | 1 |
| Bez, Y | 1 |
| Parellada, E | 1 |
| Carpiniello, B | 1 |
| Vidailhet, P | 1 |
| Schreiner, A | 7 |
| Li, J | 1 |
| Li, C | 1 |
| Moosavi, SM | 1 |
| Ahmadi, M | 1 |
| Mojtahedi, D | 1 |
| Yazdani, J | 1 |
| Monajemi, MB | 1 |
| Ganesh, M | 1 |
| Jabbar, U | 1 |
| Iskander, FH | 1 |
| Hefner, G | 1 |
| Falter, T | 1 |
| Bruns, K | 1 |
| Hiemke, C | 1 |
| Camkurt, MA | 1 |
| Gülpamuk, B | 1 |
| Casey, DE | 1 |
| Sands, EE | 1 |
| Heisterberg, J | 1 |
| Yang, HM | 1 |
| Peterson, E | 1 |
| Stoebner, A | 1 |
| Weatherill, J | 1 |
| Kutscher, E | 1 |
| Raja, M | 2 |
| Azzoni, A | 2 |
| Yamaguchi, I | 1 |
| Hamada, K | 1 |
| Yoshida, M | 1 |
| Isayama, H | 1 |
| Kanazashi, S | 1 |
| Takeuchi, K | 1 |
| Krishnakumar, P | 1 |
| Jayakrishnan, MP | 1 |
| Beegum, MN | 1 |
| Riyaz, A | 1 |
| Haas, M | 1 |
| Eerdekens, M | 3 |
| Kushner, S | 1 |
| Singer, J | 1 |
| Augustyns, I | 1 |
| Quiroz, J | 1 |
| Pandina, G | 1 |
| Kusumakar, V | 1 |
| Janicak, PG | 2 |
| Glick, ID | 1 |
| Marder, SR | 2 |
| Crandall, DT | 1 |
| McQuade, RD | 1 |
| Marcus, RN | 1 |
| Eudicone, JM | 1 |
| Assunção-Talbott, S | 1 |
| Lamkin, S | 1 |
| Buhl, D | 1 |
| Geddes, JR | 1 |
| Briess, D | 1 |
| Hsu, WY | 1 |
| Huang, SS | 1 |
| Lee, BS | 1 |
| Chiu, NY | 1 |
| Mittal, M | 1 |
| Khan, S | 1 |
| Shioda, K | 1 |
| Nisijima, K | 1 |
| Yoshino, T | 1 |
| Kato, S | 1 |
| Locatelli, I | 1 |
| Kastelic, M | 1 |
| Koprivsek, J | 1 |
| Kores-Plesnicar, B | 1 |
| Mrhar, A | 1 |
| Dolzan, V | 1 |
| Grabnar, I | 1 |
| Gaebel, W | 2 |
| Riesbeck, M | 2 |
| Wölwer, W | 2 |
| Klimke, A | 2 |
| Eickhoff, M | 2 |
| von Wilmsdorff, M | 2 |
| Lemke, M | 2 |
| Heuser, I | 1 |
| Maier, W | 2 |
| Huff, W | 1 |
| Schmitt, A | 2 |
| Sauer, H | 1 |
| Riedel, M | 1 |
| Klingberg, S | 2 |
| Köpcke, W | 2 |
| Ohmann, C | 2 |
| Möller, HJ | 5 |
| Ouyang, WC | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| Morozova, MA | 1 |
| Beniashvili, AG | 1 |
| Lepilkina, TA | 1 |
| Rupchev, GE | 1 |
| Miura, I | 1 |
| Takeuchi, S | 1 |
| Katsumi, A | 1 |
| Kanno, K | 1 |
| Watanabe, K | 1 |
| Mashiko, H | 1 |
| Niwa, S | 1 |
| Goikolea, JM | 2 |
| Colom, F | 1 |
| Torres, I | 1 |
| Capapey, J | 1 |
| Valentí, M | 1 |
| Undurraga, J | 1 |
| Grande, I | 1 |
| Sanchez-Moreno, J | 1 |
| Vieta, E | 3 |
| Katz, N | 1 |
| Zemishlany, Z | 1 |
| Weizman, A | 1 |
| Merlo, MC | 1 |
| Hofer, H | 1 |
| Gekle, W | 1 |
| Berger, G | 1 |
| Panhuber, I | 1 |
| Latour, G | 1 |
| Gianfrancesco, FD | 1 |
| Grogg, AL | 1 |
| Mahmoud, RA | 2 |
| Wang, RH | 1 |
| Nasrallah, HA | 1 |
| Yoshimura, R | 2 |
| Ueda, N | 2 |
| Shinkai, K | 2 |
| Nakamura, J | 2 |
| Kores Plesnicar, B | 1 |
| Zalar, B | 1 |
| Tomori, M | 1 |
| Krajnc, I | 1 |
| Lane, HY | 4 |
| Chang, YC | 3 |
| Cheng, YC | 1 |
| Liu, GC | 1 |
| Lin, XR | 1 |
| Chang, WH | 3 |
| Pajonk, FG | 3 |
| Peters, S | 2 |
| Rettig, K | 2 |
| Degner, D | 3 |
| Rüther, E | 2 |
| Nakagawa, S | 1 |
| Koyama, T | 1 |
| Abraham, TM | 1 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 1 |
| Berg, PH | 2 |
| Wei, H | 1 |
| Beasley, CM | 2 |
| Kane, JM | 2 |
| Grunze, H | 2 |
| Dittmann, S | 1 |
| Pae, CU | 3 |
| Lee, KU | 1 |
| Kim, JJ | 1 |
| Lee, CU | 1 |
| Bahk, WM | 3 |
| Lee, SJ | 1 |
| Lee, C | 2 |
| Paik, IH | 2 |
| Lin, CC | 1 |
| Huang, CH | 1 |
| Hsu, SK | 1 |
| Serio, RN | 1 |
| Nishimura, K | 1 |
| Omori, M | 1 |
| Horikawa, N | 1 |
| Tanaka, E | 1 |
| Furuya, T | 1 |
| Harigai, M | 1 |
| Currier, GW | 3 |
| Chou, JC | 2 |
| Feifel, D | 2 |
| Bossie, CA | 2 |
| Turkoz, I | 1 |
| Gharabawi, GM | 2 |
| Raedler, TJ | 2 |
| Naber, D | 3 |
| Wiedemann, K | 2 |
| Hirschfeld, RM | 1 |
| Keck, PE | 2 |
| Kramer, M | 2 |
| Karcher, K | 1 |
| Canuso, C | 1 |
| Grossman, F | 3 |
| Kafantaris, V | 1 |
| Coletti, DJ | 1 |
| Dicker, R | 1 |
| Padula, G | 1 |
| Pleak, RR | 1 |
| Alvir, JM | 1 |
| Lejeune, J | 1 |
| Larmo, I | 2 |
| Chrzanowski, W | 1 |
| Witte, R | 1 |
| Karavatos, A | 1 |
| Lex, A | 1 |
| Medori, R | 1 |
| Yoon, JS | 1 |
| Kim, YH | 1 |
| Lee, YH | 1 |
| Kim, KS | 1 |
| Song, HK | 1 |
| Choi, SK | 2 |
| Webber, MA | 1 |
| Mahmud, W | 1 |
| Lightfoot, JD | 1 |
| Shekhar, A | 1 |
| Shin, YC | 1 |
| Woo, JM | 1 |
| Yoon, BH | 1 |
| Lee, JS | 1 |
| Jon, DI | 1 |
| Chung, SK | 1 |
| Goto, M | 1 |
| Yamada, Y | 1 |
| Kaji, K | 1 |
| Kakihara, S | 1 |
| Kohara, K | 1 |
| Ninomiya, H | 1 |
| Egami, H | 1 |
| Maeda, H | 1 |
| Khanna, S | 1 |
| Lyons, B | 1 |
| Llinares Tello, F | 1 |
| Hernández Prats, C | 1 |
| Bosacoma Ros, N | 1 |
| Pérez Martínez, E | 1 |
| Climent Grana, E | 1 |
| Navarro Polo, JN | 1 |
| Ordovás Baines, JP | 1 |
| Treuer, T | 1 |
| Basson, BR | 1 |
| Liu, YC | 1 |
| Chiu, CC | 1 |
| Tsai, GE | 1 |
| Kraus, JE | 1 |
| Sheitman, BB | 1 |
| Cook, A | 1 |
| Reviere, R | 1 |
| Lieberman, JA | 2 |
| Veser, FH | 1 |
| Veser, BD | 1 |
| McMullan, JT | 1 |
| Zealberg, J | 1 |
| Strous, RD | 1 |
| Greenbaum, L | 1 |
| Kanyas, K | 1 |
| Merbl, Y | 1 |
| Horowitz, A | 1 |
| Karni, O | 1 |
| Viglin, D | 1 |
| Olender, T | 1 |
| Deshpande, SN | 1 |
| Lancet, D | 1 |
| Ben-Asher, E | 1 |
| Lerer, B | 1 |
| Tor, PC | 1 |
| Lee, HY | 1 |
| Tan, CH | 1 |
| Teixeira, AL | 1 |
| Maia, DP | 1 |
| Cardoso, F | 1 |
| Potkin, SG | 2 |
| Greenspan, AJ | 1 |
| Mahmoud, R | 1 |
| Kosik-Gonzalez, C | 1 |
| Rupnow, MF | 1 |
| Davidson, M | 1 |
| Burtea, V | 1 |
| Zhu, Y | 1 |
| Trivedi, JK | 1 |
| Crespo-Facorro, B | 2 |
| Pelayo-Terán, JM | 1 |
| Pérez-Iglesias, R | 2 |
| Ramírez-Bonilla, M | 2 |
| Martínez-García, O | 2 |
| Pardo-García, G | 1 |
| Vázquez-Barquero, JL | 1 |
| Gabriel, A | 1 |
| Miyaoka, T | 1 |
| Yasukawa, R | 1 |
| Yasuda, H | 1 |
| Hayashida, M | 1 |
| Inagaki, T | 1 |
| Horiguchi, J | 1 |
| Reilly, JL | 1 |
| Harris, MS | 1 |
| Keshavan, MS | 1 |
| Sweeney, JA | 2 |
| Llorca, J | 1 |
| Luis Vázquez-Barquero, J | 1 |
| Normann, C | 3 |
| Schmauss, M | 1 |
| Bakri, N | 1 |
| Gerwe, M | 1 |
| Vermeulen, A | 1 |
| Piotrovsky, V | 1 |
| Ludwig, EA | 1 |
| Schenkel, LS | 1 |
| Pavuluri, MN | 1 |
| Herbener, ES | 1 |
| Harral, EM | 1 |
| Fakra, E | 1 |
| Salgado-Pineda, P | 1 |
| Besnier, N | 1 |
| Azorin, JM | 2 |
| Blin, O | 1 |
| Hollis, CP | 1 |
| Thompson, A | 1 |
| Cohen, M | 1 |
| Panagides, J | 1 |
| Jockers-Scherübl, MC | 1 |
| Kühn, KU | 1 |
| Bechdolf, A | 1 |
| Bender, S | 1 |
| Schlösser, R | 1 |
| Schmidt, LG | 1 |
| Jäger, M | 1 |
| Buchkremer, G | 1 |
| Falkai, P | 1 |
| Häfner, H | 1 |
| Salize, HJ | 1 |
| Schneider, F | 1 |
| Lipkovich, I | 1 |
| Adams, DH | 1 |
| Mallinckrodt, C | 1 |
| Faries, D | 1 |
| Baron, D | 1 |
| Houston, JP | 1 |
| Yamamoto, N | 1 |
| Oda, T | 1 |
| Inada, T | 1 |
| Lin, SK | 1 |
| Chen, CH | 1 |
| Pan, CH | 1 |
| Høyberg, OJ | 1 |
| Fensbo, C | 1 |
| Remvig, J | 1 |
| Lingjaerde, O | 1 |
| Sloth-Nielsen, M | 1 |
| Salvesen, I | 1 |
| Heinrich, K | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Kinzler, E | 1 |
| Hruschka, H | 1 |
| Huttunen, MO | 1 |
| Piepponen, T | 1 |
| Rantanen, H | 1 |
| Nyholm, R | 1 |
| Raitasuo, V | 1 |
| Goodnick, PJ | 1 |
| Kopala, LC | 1 |
| Fredrikson, D | 1 |
| Good, KP | 1 |
| Honer, WG | 1 |
| Tohen, M | 2 |
| Zarate, CA | 2 |
| Centorrino, F | 1 |
| Hegarty, JI | 1 |
| Froeschl, M | 1 |
| Zarate, SB | 1 |
| Umbricht, D | 2 |
| Gelenberg, AJ | 1 |
| Hopkins, HS | 1 |
| Welner, M | 1 |
| Brody, AL | 1 |
| Berent, I | 1 |
| Carabeth, J | 1 |
| Cordero, MM | 1 |
| Cordero, R | 1 |
| Sugerman, B | 1 |
| Robinson, D | 1 |
| Hillard, JR | 1 |
| Miller, CH | 1 |
| Mohr, F | 1 |
| Woerner, M | 1 |
| Fleischhacker, WW | 1 |
| Andrade, C | 1 |
| Knable, MB | 1 |
| Coppola, R | 1 |
| Gorey, JG | 1 |
| Jones, DW | 1 |
| Lee, KS | 1 |
| Weinberger, DR | 1 |
| Sharif, ZA | 1 |
| Durrenberger, S | 1 |
| de Leon, J | 1 |
| Erfurth, A | 1 |
| Marcuse, A | 1 |
| Amann, B | 1 |
| Walden, J | 2 |
| Peuskens, J | 1 |
| Bech, P | 1 |
| Bale, R | 1 |
| Fleurot, O | 1 |
| Rein, W | 1 |
| Chiu, WC | 1 |
| Wu, ST | 1 |
| Su, MH | 1 |
| Doig, A | 1 |
| Sembhi, S | 1 |
| Livingston, G | 1 |
| Eidelman, I | 1 |
| Seedat, S | 1 |
| Stein, DJ | 1 |
| Lal, S | 1 |
| Iskandar, H | 1 |
| Takahashi, H | 1 |
| Ghaemi, SN | 2 |
| Hesslinger, B | 1 |
| Simpson, GM | 1 |
| Czekalla, J | 1 |
| Dellva, MA | 1 |
| Grundy, S | 1 |
| Letmaier, M | 1 |
| Schreinzer, D | 1 |
| Wolf, R | 1 |
| Kasper, S | 1 |
| Miller, DS | 1 |
| Yatham, LN | 2 |
| Lam, RW | 1 |
| de Haan, L | 1 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Dingemans, P | 1 |
| Linszen, D | 1 |
| Kim, DJ | 1 |
| Kim, W | 1 |
| Yoon, SJ | 1 |
| Go, HJ | 1 |
| Choi, BM | 1 |
| Jun, TY | 1 |
| Kim, YK | 1 |
| Kerbusch, T | 1 |
| Mathôt, RA | 1 |
| Otten, HM | 1 |
| Meesters, EW | 1 |
| van Kan, HJ | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Sachs, GS | 1 |
| Okamoto, A | 1 |
| Bowden, CL | 1 |
| Pelzer, E | 1 |
| Kissling, W | 1 |
| Riehl, T | 1 |
| Wernicke, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590] | Phase 3 | 24 participants (Actual) | Interventional | 2005-11-30 | Terminated | ||
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616] | Phase 3 | 13 participants (Actual) | Interventional | 2004-04-30 | Terminated | ||
| A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward[NCT00418873] | Phase 4 | 39 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Study was stopped due to difficulty in patient enrollment) | ||
| The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone[NCT00034749] | Phase 3 | 279 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741] | 180 participants (Anticipated) | Observational | 2023-01-09 | Recruiting | |||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.[NCT00257075] | Phase 3 | 267 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder[NCT00249236] | Phase 3 | 291 participants (Actual) | Interventional | 2001-03-31 | Completed | ||
| NMDA Enhancers in the Treatment of Schizophrenia[NCT00328276] | Phase 2 | 20 participants | Interventional | 2004-12-31 | Completed | ||
| NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine[NCT00491569] | Phase 2 | 60 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia[NCT00159081] | Phase 4 | 159 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149] | Phase 3 | 158 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
21 reviews available for risperidone and Acute Disease
| Article | Year |
|---|---|
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action P | 2020 |
Acute Laryngeal Dystonia With Novel Antipsychotics: A Case Report and Review of Literature.
Topics: Acute Disease; Aged; Antipsychotic Agents; Dystonia; Humans; Laryngeal Diseases; Male; Risperidone; | 2015 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
Bipolar disorder.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; H | 2007 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disord | 2013 |
[Extrapyramidal syndrome].
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazep | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].
Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 2003 |
Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
Topics: Acute Disease; Antipsychotic Agents; Chronic Disease; Humans; Risperidone; Schizophrenia | 2004 |
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodia | 2005 |
Atypical antipsychotics: newer options for mania and maintenance therapy.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Humans; | 2005 |
Risperidone: efficacy and safety.
Topics: Acute Disease; Antipsychotic Agents; Double-Blind Method; Humans; Randomized Controlled Trials as To | 1995 |
Antipsychotic dosing strategies in acute schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administratio | 1996 |
Antipsychotics in bipolar disorder.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; D | 1996 |
Antipsychotic agents and bipolar disorder.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cl | 1998 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration | 1998 |
Common treatment goals of antipsychotics: acute treatment.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedu | 1998 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep | 2000 |
The role of novel antipsychotics in bipolar disorders.
Topics: Acute Disease; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Lithium; Ol | 2002 |
56 trials available for risperidone and Acute Disease
| Article | Year |
|---|---|
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle A | 2019 |
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Me | 2013 |
An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiepins; Female; Hospitalization; Humans; Hyperp | 2013 |
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combin | 2014 |
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Female; Humans; Male; Paliperidone | 2015 |
Comparison of Quetiapine and Risperidone in Treatment of Acute Psychosis: A Double-Blind, Randomized-Controlled Study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Humans; | 2015 |
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzoxazoles; Body Weight; Cholesterol; Dose-Response Re | 2008 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manu | 2008 |
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Meth | 2009 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol | 2010 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognition Disorders; Drug Therapy, Combination; Humans; | 2012 |
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Fema | 2012 |
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.
Topics: Acute Disease; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Mal | 2003 |
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-I | 2003 |
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
Topics: Acute Disease; Adult; Age Factors; Age of Onset; Antipsychotic Agents; Body Weight; Dose-Response Re | 2003 |
[Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Female; Humans; Male; Prospective Studies; P | 2003 |
Comparison of three antipsychotics in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Emergency Services, | 2003 |
Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Depression; Female; Gen | 2004 |
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Cluster Analysis | 2004 |
Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; M | 2004 |
Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study.
Topics: Acute Disease; Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bri | 2004 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Asia; Basal Ganglia Diseases; Bipolar Disorder; Drug The | 2004 |
Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseas | 2005 |
An open study of risperidone liquid in the acute phase of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 2005 |
Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; | 2005 |
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; M | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; | 2005 |
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Meth | 2006 |
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Fem | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F | 2007 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc | 2006 |
Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chemistry, Pharmaceutical; Endpoint De | 2006 |
Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Computer S | 2007 |
Facial emotion processing in acutely ill and euthymic patients with pediatric bipolar disorder.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; | 2007 |
Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study.
Topics: Acute Disease; Adolescent; Adult; Affect; Antipsychotic Agents; Diagnostic and Statistical Manual of | 2009 |
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; D | 2007 |
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Algorithms; Antipsychotic Agents; Biomedical Research; Cooperative Behavior; D | 2007 |
Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Capsules; Diagnostic and Statistical Ma | 2008 |
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isox | 1993 |
Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Me | 1994 |
Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Clopenthixol; Double-Blind Method; Fem | 1995 |
Risperidone in the treatment of mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Confidence Intervals; D | 1996 |
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antipsychotic Agents; Ba | 1998 |
Tiagabine appears not to be efficacious in the treatment of acute mania.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; GABA Ant | 1999 |
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H | 1999 |
Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.
Topics: Acute Disease; Adult; Antipsychotic Agents; Asian People; Drug Administration Schedule; Female; Hosp | 2000 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
Effect of risperidone on serum cytokines.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cytokines; Female; Humans; Immune System; Male; Risperid | 2001 |
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents | 2002 |
57 other studies available for risperidone and Acute Disease
| Article | Year |
|---|---|
Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD.
Topics: Acute Disease; Attention Deficit Disorder with Hyperactivity; Child; Conduct Disorder; Humans; Pancr | 2022 |
Abrupt Late-onset Psychosis as a Presentation of Coronavirus 2019 Disease (COVID-19): A Longitudinal Case Report.
Topics: Acute Disease; Antipsychotic Agents; COVID-19; COVID-19 Nucleic Acid Testing; Humans; Longitudinal S | 2021 |
Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study.
Topics: Acute Disease; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic | 2017 |
An Unexpected Circumstance: Acute Dystonic Reaction in the Setting of Clozapine Administration.
Topics: Acute Disease; Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Dystonia; Humans; Male; Ps | 2019 |
Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; I | 2019 |
Psychosis improved dysphonia.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clonazepam; Diagnosis, Differential | 2013 |
The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Female; Humans; Male; Medication Adherence; Psychiatric Status | 2014 |
Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Drug Combinations; Drug Therapy, Combination | 2016 |
Elevated risperidone serum concentrations during acute inflammation, two cases.
Topics: Acute Disease; Adult; Antipsychotic Agents; C-Reactive Protein; Female; Humans; Inflammation; Middle | 2015 |
Acute Onset of Xanthopsia Associated With Risperidone.
Topics: Acute Disease; Adult; Antipsychotic Agents; Color Vision Defects; Female; Humans; Risperidone | 2016 |
Case of acute psychosis from herbal supplements.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dietary Supplements; Female; Haloperidol; Humans; Loraze | 2008 |
Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Anti-Inflammatory Agents; Choline Deficiency; Ethionine; Female; I | 2009 |
Acute disseminated encephalomyelitis presenting as acute psychotic disorder.
Topics: Acute Disease; Anti-Inflammatory Agents; Antipsychotic Agents; Child; Child, Preschool; Diagnosis, D | 2008 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesi | 2009 |
Starvation causes acute psychosis due to anterior thalamic infarction.
Topics: Acute Disease; Adult; Antipsychotic Agents; Factor V; Female; Humans; Infarction; Ketosis; Positron- | 2010 |
Effect of risperidone on acute methamphetamine-induced hyperthermia in rats.
Topics: Acute Disease; Animals; Chronic Disease; Fever; Male; Methamphetamine; Rats; Rats, Wistar; Risperido | 2010 |
A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Area Under Curve; Base Sequence; Bayes Theorem; Cytochrome P-45 | 2010 |
Ibuprofen and psychotic exacerbation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Back Pain; Como | 2002 |
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte | 2002 |
Risperidone liquid treatment of acute mania.
Topics: Acute Disease; Aged; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Risperidone | 2003 |
Switching to quetiapine in patients with acute mania who were intolerant to risperidone.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug A | 2004 |
Acute delirium associated with combined diphenhydramine and linezolid use.
Topics: Acetamides; Acute Disease; Delirium; Diphenhydramine; Drug Combinations; Drug Interactions; Duty to | 2004 |
Risperidone in the treatment of acute confusional state (delirium) due to neuropsychiatric lupus erythematosus: case report.
Topics: Acute Disease; Antipsychotic Agents; Confusion; Female; Humans; Lupus Erythematosus, Systemic; Middl | 2003 |
Risperidone in the treatment of acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Risperidone; Schizophreni | 2004 |
Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin.
Topics: Acute Disease; Adult; Antipsychotic Agents; Compartment Syndromes; Drug Interactions; Humans; Hyperl | 2004 |
Acute cholestatic hepatitis probably associated with risperidone.
Topics: Acute Disease; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Ag | 2005 |
Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania?
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Trials as Topic; Human | 2005 |
Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Genotype; Humans; Linkage Dise | 2007 |
Mefloquine-induced mania in a 22-year-old Chinese man.
Topics: Acute Disease; Adult; Animals; Antimalarials; Bipolar Disorder; Chloroquine; Contraindications; Huma | 2006 |
Psychosis following acute Sydenham's chorea.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Chorea; Fear; Hallucinations; Humans; Male; Mitral | 2007 |
Gender-specific effects in the treatment of acute schizophrenia with risperidone.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; | 2006 |
Changes in plasma cholesterol in mood disorder patients: does treatment make a difference?
Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; A | 2007 |
Possible antipsychotic effects of minocycline in patients with schizophrenia.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antipsychotic Agents; Electroencephalography; Haloperid | 2007 |
Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Mem | 2006 |
Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
Topics: Acute Disease; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2007 |
Evaluating dose response from flexible dose clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relatio | 2008 |
Three cases of schizophrenia for which olanzapine was effective after early acute phase.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Foll | 2008 |
Risperidone treatment of refractory acute mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Isoxazoles; Male; Pipe | 1995 |
Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Admin | 1996 |
Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis.
Topics: Acute Disease; Adult; Antipsychotic Agents; Depressive Disorder; Humans; Male; Monoamine Oxidase Inh | 1996 |
Acute dystonia induced by rapid increase in risperidone dosage.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dystonia; Humans; Male; Risperidone; Schizophrenia, Para | 1996 |
Pancreatitis associated with risperidone treatment?
Topics: Acute Disease; Adult; Humans; Male; Pancreatitis; Risperidone; Schizophrenia | 1997 |
Risperidone may worsen fluoxetine-treated OCD.
Topics: Acute Disease; Adult; Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Drug Th | 1998 |
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Hu | 1998 |
Acute dystonic reaction to lithium and risperidone.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Dystonia; Humans; Li | 1999 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Acute confusional states during treatment with risperidone.
Topics: Acute Disease; Aged; Antipsychotic Agents; Confusion; Humans; Male; Risperidone; Schizophrenia | 2000 |
Risperidone in the treatment of acute stress disorder in physically traumatized in-patients.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Arm Injuries; Female; Foot Injuries; Humans; Male; | 2000 |
St. John's wort and schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypericum; Male; Olanza | 2000 |
Acute dystonia induced by adding midodrine, a selective alpha 1 agonist, to risperidone in a patient with catatonic schizophrenia.
Topics: Acute Disease; Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Dystonia; Female; Humans; Mid | 2000 |
Acute and long-term treatment of catatonia with risperidone.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Long-Term Care; Male; | 2001 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper | 2000 |
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen | 2001 |
Topiramate as a mood stabilizer.
Topics: Acute Disease; Adaptation, Psychological; Adult; Antimanic Agents; Bipolar Disorder; Clonazepam; Dos | 2001 |
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepine | 2001 |
Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.
Topics: Acute Disease; Acute Kidney Injury; Adult; Antimanic Agents; Antipsychotic Agents; Bayes Theorem; Bi | 2002 |
Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Female; Humans; Isoxazoles; Male; Middl | 1991 |